NuCana plc - American Depositary Share (NCNA): Price and Financial Metrics
GET POWR RATINGS... FREE!
NCNA Stock Price Chart Interactive Chart >
NCNA Price/Volume Stats
| Current price | $1.51 | 52-week high | $3.32 |
| Prev. close | $1.46 | 52-week low | $0.52 |
| Day low | $1.47 | Volume | 70,333 |
| Day high | $1.54 | Avg. volume | 153,495 |
| 50-day MA | $1.03 | Dividend yield | N/A |
| 200-day MA | $1.07 | Market Cap | 78.79M |
NuCana plc - American Depositary Share (NCNA) Company Bio
NuCana plc develops anti-cancer medicines for ovarian, biliary, pancreatic, colorectal, haematology, oncology, and breast cancers. NuCana produces oncology medicines using a proprietary technology platform for cancer patients. The company was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
Latest NCNA News From Around the Web
Below are the latest news stories about NUCANA PLC that investors may wish to consider to help them evaluate NCNA as an investment opportunity.
NuCana Regains Compliance with Nasdaq Minimum Bid Price RequirementEDINBURGH, United Kingdom, Jan. 23, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the matter is |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! |
NuCana: Pipeline And Major Gilead Litigation Progressing Nicely (NASDAQ:NCNA)NuCana’s market cap is not reflecting potential of two other drug candidates NUC-3373 and NUC-7738, currently in Phase 2 trials. See why I rate NCNA stock a strong buy. |
NuCana plc: NuCana Announces Receipt of NASDAQ NoticeEDINBURGH, United Kingdom, Jan. 06, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC … |
NuCana Announces Receipt of NASDAQ NoticeEDINBURGH, United Kingdom, Jan. 06, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated January 3, 2023, indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares (“ADSs”) for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5450(a)(1). The Notification Letter h |
NCNA Price Returns
| 1-mo | 128.79% |
| 3-mo | 43.81% |
| 6-mo | -16.57% |
| 1-year | -47.02% |
| 3-year | -71.62% |
| 5-year | -93.77% |
| YTD | 128.79% |
| 2022 | -72.27% |
| 2021 | -46.99% |
| 2020 | -26.39% |
| 2019 | -57.93% |
| 2018 | 43.42% |
Loading social stream, please wait...